PF-AtlasКлинические испытания › NCT04268485

Longitudinal Changes in Serum KL-6 in IPF

Serum KL-6 level · Не указано

ID реестра
NCT04268485
Фаза
Не указано
Статус
Неизвестно
Препарат / вмешательство
Serum KL-6 level
Спонсор
Manchester University NHS Foundation Trust
Начало
2021-02-01
Набор участников
60
Центры
1

Об исследовании

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with a poor prognosis. More accurate tests to predict disease progression and response to treatment are required. Krebs von den Lungen-6 (KL-6) is a blood marker associated with IPF. Results from previous studies have shown that levels of KL-6 are higher in patients with IPF compared to people without the disease. In addition, it is not clear what impact treatment has on KL-6 levels, and whether this could help us to monitor how effective treatment for IPF is. The investigators plan to perform a study in which KL-6 levels in the blood of patients with a new diagnosis of IPF are measured at baseline, 3, 6 and 12 months to look for and changes in the levels of KL-6 in the blood.

Открыть NCT04268485 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT04268485 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.